|Title||Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Krens, Stefanie D., Howard L. McLeod, and Daniel L. Hertz|
|Date Published||2013 Apr|
|Keywords||Antineoplastic Agents, Breast Neoplasms, Bridged-Ring Compounds, Docetaxel, Drug Monitoring, Female, Humans, Neoplasms, Paclitaxel, Pharmacogenetics, Precision Medicine, Taxoids|
The taxanes are a class of chemotherapeutic agents that are widely used in the treatment of various solid tumors. Although taxanes are highly effective in cancer treatment, their use is associated with serious complications attributable to large interindividual variability in pharmacokinetics and a narrow therapeutic window. Unpredictable toxicity occurrence necessitates close patient monitoring while on therapy and adverse effects frequently require decreasing, delaying or even discontinuing taxane treatment. Currently, taxane dosing is based primarily on body surface area, ignoring other factors that are known to dictate variability in pharmacokinetics or outcome. This article discusses three potential strategies for individualizing taxane treatment based on patient information that can be collected before or during care. The clinical implementation of pharmacogenetics, enzyme probes or therapeutic drug monitoring could enable clinicians to personalize taxane treatment to enhance efficacy and/or limit toxicity.
|Original Publication||Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.|
|PubMed Central ID||PMC3975654|
|Grant List||P01 CA142538 / CA / NCI NIH HHS / United States |
UL1 RR025747 / RR / NCRR NIH HHS / United States
UL1RR025747 / RR / NCRR NIH HHS / United States
P01CA142538 / CA / NCI NIH HHS / United States
Pharmacogenetics, enzyme probes and therapeutic drug monitoring as potential tools for individualizing taxane therapy.